A Registration Route Decision Model for the Russian Market

1. Key takeaways

At project initiation, GRZAN applies a decision model built on three inputs and a two-level sort: the inputs are the number of target member states, the maturity of the existing evidence package, and whether submission before December 31, 2027 is achievable; the sort first asks whether a national-pathway filing is necessary, then evaluates the size of the evidence gap. The model outputs a pathway label and a priority for each registration unit, rather than a single blanket choice between national and Union registration.

The value of the model lies in its granularity. Portfolios almost never justify one uniform answer: the flagship product with mature evidence may go Union-wide, while a niche accessory without clinical data may need the national window. Producing a per-unit decision card forces those distinctions into the open at the start, when options are still cheap to change.

The quality of the model’s outputs is bounded by the quality of its inputs, so the three inputs deserve definition. Market count should be taken from the commercial plan per registration unit, not from aspirational territory lists; evidence maturity should be assessed against the specific requirements of the chosen pathway, with each component scored on its own validity status; and submission feasibility should be tested against the statutory durations plus trial time, rather than against best-case administrative processing. When these definitions are fixed in a short internal guideline, different assessors reach comparable conclusions, and the quarterly re-run becomes a genuine trend signal instead of a subjective re-estimate.

2. Legal basis

The model operates against the fixed regulatory anchors of both pathways. The table below lists the instruments whose dates and clauses supply the model’s hard constraints.

3. Expert insights

Insight one: first ask whether it is possible, then ask whether it is worthwhile. Because the window closes at the end of 2027, the first sort must screen on the question of whether submission within the window can be completed; the second sort handles commercial optimization. When back-planning the schedule, use the statutory durations (31 working days / 50 working days) as the floor, then add the time required for trials and clinical arrangements. A submission month that only works if every review round is passed without deficiencies is not a plan; it is a hope, and the model should flag it as such.

Insight two: evidence maturity must be measured separately by component. Technical test reports, biological evaluation, QMS documentation and clinical data each carry different validity requirements. If the QMS certificate and production inspection arrangement fall within the last two years, they can directly serve the Union pathway; if the manufacturer holds only a Chinese-language instruction leaflet and domestic test reports, the gap will be magnified. Scoring the four components separately, instead of using one overall maturity rating, is what makes the second sort meaningful and prevents optimistic aggregate scores from masking a single disqualifying gap.

Insight three: a dual-track mix within one company is legitimate. The law does not require all products of a manufacturer to follow the same pathway. Choosing the national pathway for products with current certification urgency while placing long-range portfolio bets on the Union pathway is a common and reasonable combination. The only structural requirement is discipline: each certificate must be mapped to its applicable post-market rules, and the two regimes must be administered by clearly assigned internal owners so that neither set of obligations is lost between teams.

Finally, the model’s cadence matters as much as its logic. A decision model run once at project start encodes the assumptions of that moment; regulations, evidence positions and market plans all move afterwards. The quarterly re-run recommended above should be treated as a governance event with a fixed owner, a short agenda — window remaining time, regulatory changes, evidence status per unit — and recorded decisions, so that pathway changes are made deliberately rather than discovered late. The output of each run is a refreshed set of pathway labels and priorities, plus a short exception list of units whose recommendation changed; those exceptions are where management attention belongs, because a changed label usually means a changed deadline, budget or market commitment somewhere downstream.

4. Practical recommendations

1. Create a decision card for every registration unit containing six elements: type code, risk class, target countries, evidence list, gap list, and expected submission month. Keep the cards in a single register so that pathway choices can be compared and aggregated across the portfolio.
2. Re-run the pathway model quarterly, focusing on the remaining window time and new regulatory developments, such as the evidence requirement changes introduced by Orders No. 421н and No. 540н. A quarterly cadence catches drift early while still leaving room for corrective action within the window.
3. For products that must reach the market after 2027, complete the Union-pathway dossier gap assessment within 2026 and start closing the gaps. Sequencing the evidence work early converts the transition deadline from a constraint into a planned milestone on the launch calendar.

5. Verification checklist

• □ Every registration unit has a decision card containing the six elements
• □ The submission month on the card falls before December 31, 2027 (national-pathway option)
• □ The evidence gap list for the Union pathway portion has been completed
• □ For dual-track mixes, the applicable post-market rules for each certificate have been confirmed
• □ An owner has been assigned for the quarterly re-verification mechanism

Regulatory information verified as of October 29, 2026.

GRZAN supports medical device manufacturers entering the Russian market with end-to-end regulatory services covering both registration pathways: national registration under ПП РФ No. 1684, including route selection among clauses 63, 87 and 101, and EAEU registration under ЕЭК Decision No. 46, together with classification strategy support under Decision No. 173 as amended. Our team helps define the optimal route for each registration unit, prepare dossiers and testing plans, coordinate with RZN and expert institutions, and track transition deadlines through December 31, 2027. For tailored support on Russia market entry, pathway selection and dossier preparation, contact GRZAN at info@grzanglobal.com.